Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pasireotide - RECORDATI

Next Previous
X
Search
Drug Profile

Pasireotide - RECORDATI

Alternative Names: Pashireochidopamo salt; pasireotide LAR; Pasireotide pamoate; SIGNIFOR; SIGNIFOR LAR; SOM 230; SOM 230 LAR; SOM230C

Latest Information Update: 23 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer H. Lee Moffitt Cancer Center and Research Institute; Novartis; Recordati; UNC Lineberger Comprehensive Cancer Center; University of Arkansas for Medical Sciences; University of Miami
  • Class Analgesics; Antineoplastics; Antisecretories; Cyclic peptides; Macrocyclic compounds; Oligopeptides; Peptidomimetics
  • Mechanism of Action Corticotropin-releasing hormone inhibitors; Growth hormone-releasing hormone inhibitors; Insulin-like growth factor I inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acromegaly; Pituitary ACTH hypersecretion; Neuroendocrine tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acromegaly; Gigantism; Pituitary ACTH hypersecretion
  • Phase II Cluster headache; Hypoglycaemia; Pituitary cancer
  • Discontinued Carcinoid tumour; Gastrointestinal cancer; Gastrointestinal disorders; Liver cancer; Malignant melanoma; Meningioma; Merkel cell carcinoma; Neuroendocrine tumours; Pancreatic cancer; Pancreatic disorders; Prostate cancer; Radiation injuries; Uveal melanoma

Most Recent Events

  • 04 Jan 2024 Phase-II clinical trials in Hypoglycaemia in Switzerland (SC) (NCT05928390)
  • 03 Jul 2023 Recordati plans a phase II trial for Hypoglycaemia (IV) in October 2023 (NCT05928390)
  • 02 Mar 2023 H. Lee Moffitt Cancer Center and Research Institute in collaboration with Novartis and Recordati complete a phase II trial for Neuroendocrine tumours (Metastatic disease; Inoperable/Unresectable) in the US (IM) (NCT01253161)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top